Article Text
PDF
Abstract
Introduction Inflammation plays an essential role in tumour development in cancer initiation, progression and metastasis. Immune cell components of blood count offer an attractive measure of inflammation being part of routine clinical care at minimal cost and inconvenience to the patient. It is hypothesised that raised Neutrophil Lymphocyte Ratio (NLR) and Platelet Lymphocyte Ratio (PLR) are two such markers associated with poor prognosis in ovarian cancer. Hence, this study was conducted to find association NLR and PLR with survival outcome in ovarian cancer.
Methods This study was conducted in a tertiary care teaching hospital after ethical clearance from Institutional ethics committee and written informed consent from all patients recruited. Records of 260 ovarian cancer cases admitted over five years were retrospectively searched for pretreatment neutrophil, lymphocyte and platelet counts to calculate NLR and PLR. Details of demography, disease characteristics, treatment and recurrence were recorded. Survival outcomes were correlated with the NLR and PLR. Statistical analysis was performed on SPSS version 21using ROC curves and correlation analysis.
Results NLR and PLR had negative correlation with 5-year overall survival rate. ROC analysis showed that NLR below 2.8 was associated with 5 year OS of 72.2% while NLR above 2.8 was associated with OS of 27.8%. PLR below 204 was associated with 5 year OS of 77.7% while that above 204 was associated with 5 year OS of 22.3%.
Conclusion/Implications Both Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio are independent prognostic inflammatory markers for survival of ovarian cancer.